Redondo A, Girones R, Ruiz N, Iglesias M, Mendiola C, Santaballa A, et al. Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study). Eur J Gynaecol Oncol 2021;42(6):1116-23.
DOI: 10.31083/j.ejgo4206163
Lacey JV. Ovarian neoplasia. In: Robboy SL, Mutter GL, Prat J, Bentley RC, Russell P, Anderson MC (eds.). Robby’s Pathology of the Female Reproductive Tract, 2nd edition. Oxford: Churchill Livingstone; 2009.
Cree IA, White va, Indave BI, Lokuhetty D. Female Genital Tumours. 5th ed. Internal Agency for Research on Cancer (IARC); 2020.
Suster NK, Virant-Klun I. Presence and role of stem cells in ovarian cancer. World J Stem Cells 2019;11(7):383-97.
DOI: 10.4252/wjsc.v11.i7.383
International Agency for Research on Cancer. WHO Data Visualization Tools for Exploring the Global Cancer Burden in 2022 [accessed on 24 June 2024].
Sociedad de Oncología Médica (SEOM). Las cifras del cáncer en España 2024. SEOM; 2024. p. 1-40. Disponible en: https://www.seom.org/images/LAS_CIFRAS_2024.pdf
Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Prz Menopauzalny 2023;22(2):93-104.
DOI: 10.5114/pm.2023.128661
Levine DA, Gaillard SL, Lin LL, Chi DS, Berchuck A, Dizon DS, et al. Manual de Oncología Ginecológica. Principios y práctica. Filadelfia (EE. UU.): Lippincott Williams & Wilkins; 2021. p. 393-8.
Bandera EV, Lee VS, Rodríguez-Rodríguez L, Powell CB KL. Racial/ethnic disparities in ovarian cancer treatment and survival. Clin Cancer Res 2016;22:5909-14.
DOI: 10.1158/1078-0432.CCR-16-1119
Chan JK, Zhang M, Hu JM, Shin JY, Osann K KD. Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol 2008;97:103-7.
DOI: 10.1002/jso.20932
Chan JK, Liu J, Song J, Xiang C, Wu E, Kalilani L, et al. Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer. Am J Clin Oncol Cancer Clin Trials 2023;46(7):314-22.
DOI: 10.1097/COC.0000000000001010
Reid RL, Shi J, Monnette A, Wallace KL, Oncology US, On M. Real-world progression-free and overall survival for patients with advanced ovarian cancer utilizing PARP inhibitor second-line maintenance therapy vs active surveillance. J Clin Oncol 2023;40(Suppl.16):10585.
DOI: 10.1200/JCO.2022.40.16_suppl.e18812
Banerjee S, González-Martín A, Harter P, Lorusso D, Moore KN, Oaknin A, et al. First-line PARP inhibitors in ovarian cancer: Summary of an ESMO Open - Cancer Horizons round-table discussion. ESMO Open 2020;5(6):1-10.
DOI: 10.1136/esmoopen-2020-001110
Disilvestro P, Banerjee S, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol 2023;41(3):609-17.
DOI: 10.1200/JCO.22.01549
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2018;379:2495-505.
DOI: 10.1056/NEJMoa1810858
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2019;381(25):2391-402.
DOI: 10.1056/NEJMoa1910962
Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023;34(8):681-92.
DOI: 10.1016/j.annonc.2023.05.005
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1 / 2 randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(9):1274-84.
DOI: 10.1016/S1470-2045(17)30469-2
Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. J Clin Oncol 2019;37(32):2968-73.
DOI: 10.1200/JCO.18.02238
Guevara M, Molinuevo A, Salmerón D, Marcos-Gragera R, Carulla M, Chirlaque M-D, et al. Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN). Cancers (Basel) 2022;14(10):1-18.
DOI: 10.3390/cancers14102441
Somasegar S, Reddy RA, Karam A. Trends in ovarian cancer incidence and incidence-based mortality: A 15-year population-based analysis. J Clin Oncol 2023;41(Suppl.16):5570-5570.
DOI: 10.1200/JCO.2023.41.16_suppl.5570
Saavalainen L, Lassus H, But A, Tiitinen A, Härkki P, Gissler M, et al. Risk of gynecologic cancer according to the type of endometriosis. Obs Gynecol 2018;131(6):1095-102.
DOI: 10.1097/AOG.0000000000002624
Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type i and type II. Biomed Res Int 2014;2014.
DOI: 10.1155/2014/934261
Varier L, Sundaram SM, Gamit N, Warrier S. An Overview of Ovarian Cancer: The Role of Cancer Stem Cells in Chemoresistance and a Precision Medicine Approach Targeting the Wnt Pathway with the Antagonist sFRP4. Cancers (Basel) 2023;15(4).
DOI: 10.3390/cancers15041275
Kurman RJ, Shih I-M. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. Am J Surg Pathol 2010;34(3):433-43.
DOI: 10.1097/PAS.0b013e3181cf3d79
DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman and Roseberg’s Cancer Principles and Practice of Oncology. Philadelphia: Wolkers Kluwer; 2008. p. 674.
Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010;171(1):45-53.
DOI: 10.1093/aje/kwp314
Cancer Stat Facts: Ovarian Cancer. Cancer.gov. Available at: https://seer.cancer.gov/statfacts/html/ovary.html [accessed on 30 June, 2024).
Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obs 2021;155(Suppl.1):61-85.
DOI: 10.1002/ijgo.13878
Crijnen TE, Janssen-Heijnen ML, Gelderblom H, Morreau J, Nooij MA, Kenter GG, et al. Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer 2005;4(4):301-5.
DOI: 10.1007/s10689-005-6573-2
Watson P, Bützow R, Lynch HT, Mecklin JP, Järvinen HJ, Vasen HF, et al. The clinical features of ovarian cacner in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001;82(2):223-8.
DOI: 10.1006/gyno.2001.6279
Khenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317(23):2402-16.
DOI: 10.1001/jama.2017.7112
Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011;105(9):1436-42.
DOI: 10.1038/bjc.2011.371
Salehi F, Dunfield L, Philips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Env Heal B Crit Rev 2008;11(3-4):301-21.
DOI: 10.1080/10937400701876095
Samuel D, Díaz-Barbe A, Pinto A, Schlumbrecht M GS. Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2. Cells 2022;11(539).
DOI: 10.3390/cells11030539
Mitric C, Salman L, Abrahamyan L, Kim SR, Pechlivanoglou P, Chan KKW, et al. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol 2023;170(133-42).
DOI: 10.1016/j.ygyno.2022.12.008
Leskela S, Romero I, Cristóbal E, Pérez-Mies B, Rosa-Rosa JM, Gutiérrez-Pecharroman A, et al. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences. Am J Surg Pathol 2020;44(5):649-56.
DOI: 10.1097/PAS.0000000000001432
Palles C, Martín L, Domingo E, Chegwidden L, McGuire J, Cuthill V, et al. The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management. Fam Cancer 2022;21(197-209).
DOI: 10.1007/s10689-021-00256-y
McGarrity TJ, Amos CI, Baker MJ. Peutz-Jeghers Syndrome. 2001 Feb 23 [Updated 2021 Sep 2]. In: Adam MP, Mirzaa GM, Pagon RA, et al. (editors). GeneReviews® [Internet]. Seattle (USA): University of Washington, Seattle; 1993-2023.
Bögershausen N, Wollnik B. Mutational Landscapes and Phenotypic Spectrum of SWI/SNF-Related Intellectual Disability Disorders. Front Mol Neurosci 2018;11(252).
DOI: 10.3389/fnmol.2018.00252
Kershaw V, Hickey I, Wyld L JS. The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis. Eur J Obs Gynecol Reprod Biol 2021;265:7-17.
DOI: 10.1016/j.ejogrb.2021.08.001
Sroczynski G, Gogollari A, Kuehne F, Hallsson LR, Widschwendter M, Pashayan N, et al. A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. Cancer Prev Res 2020;13(5):429-42.
DOI: 10.1158/1940-6207.CAPR-19-0506
Lim N, Hickey M, Young GP, Macrae FA, Kelly C. Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review. Int J Gynecol Cancer 2022;32(5):646-55.
DOI: 10.1136/ijgc-2021-003132
Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al; EGC. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol 2023;34(1):33-47.
DOI: 10.1016/j.annonc.2022.10.004
Liu YL, Breen K, Catchings A, Ranganathan M, Latham A, Goldfrank DJ, et al. Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncol Pr 2022;18(3):201-9.
DOI: 10.1200/OP.21.00382
Bartiromo L, Schimberni M, Villanacci R, Mangili G, Ferrari S, Ottolina J, et al. A Systematic Review of Atypical Endometriosis-Associated Biomarkers. Int J Mol Sci 2022;23(8).
DOI: 10.3390/ijms23084425
Grandi G, Toss A, Cortesi L, Botticelli L, Volpe A, Cagnacci A. The Associationi between endometriomas and ovarian cancer: preventive effect of inhibing ovulation and menstruation during reproductive life. BioMed Res Int 2015;751571.
DOI: 10.1155/2015/751571
Angelsio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, et al. Cancer- associated mutations in endometriosis without cancer. N Engl J Med 2017;376(19):1835-48.
DOI: 10.1056/NEJMoa1614814
Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 2007;43(4):690-709.
DOI: 10.1016/j.ejca.2006.11.010
Grosso G, Bella F, Godos J, Sciacca S, Del Rio D, Ray S, et al. Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. Nutr Rev 2017;75(6):405-19.
DOI: 10.1093/nutrit/nux012
Præstegaard C, Jensen A, Jensen SM, Nielsen TSS, Webb PM, Nagle CM, et al. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. Int J Cancer 2017;140(11):2422-35.
DOI: 10.1002/ijc.30600
Collaborative Group On Epidemiological Studies Of Ovarian Cancer; Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015;385(9980):1835-42.
DOI: 10.1016/S0140-6736(14)61687-1
Harris HR, Babic A, Webb PM, Nagle CM, Jordan SJ, Risch HA, et al. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: evidence from the ovarian cancer association consortium. Cancer Epidemiol Biomarkers Prev 2018;27(2):174-82.
DOI: 10.1158/1055-9965.EPI-17-0655
Harris HR, Terry KL. Polycistic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract 2016;2:14.
DOI: 10.1186/s40738-016-0029-2
Camargo MC, Stayner LT, Straif K, Reina M, Al-Alem U, Demers PA, et al. Occupational exposure to asbestos and ovarian cancer: a meta-analysis. Environ Health Perspect 2011;119(9):1211-7.
DOI: 10.1289/ehp.1003283
Guan X, Wei R, Yang R, Lu Z, Liu E, Zhao Z, et al. Association of radiotherapy for rectal cancer and second gynecological malignant neoplasms. JAMA Netw Open 2021;4(1):e2031661.
DOI: 10.1001/jamanetworkopen.2020.31661
Konishi I, Abiko K, Hayashi T, Yamanoi K, Murakami R, Yamaguchi K, et al. Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics. J Gynecol Oncol 2022;33(5):e83.
DOI: 10.3802/jgo.2022.33.e83
Van Baal JOAM, Van Noorden CJF, Nieuwland R, Van de Vijver KK, Sturk A, Van Driel WJ, et al. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. J Histochem Cytochem 2018;66(2):67-83.
DOI: 10.1369/0022155417742897
Kleppe M, Kraima AC, Kruitwagen RFPM, Van Gorp T, Smit NN, Van Munsteren JC, et al. Understanding lymphatic drainage pathways of the ovaries to predict sites for sentinel nodes in ovarian cancer. Int J Gynecol Cancer 2015;25(8):1405-14.
DOI: 10.1097/IGC.0000000000000514
Número de descargas:
1448
Número de visitas:
102
Citas:
0
